Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label Rollover Study of Levosimendan in Patients With Pulmonary Hypertension With Heart Failure and Preserved Left Ventricular Ejection Fraction (PH-HFpEF)

Next Previous
Trial Profile

Open-Label Rollover Study of Levosimendan in Patients With Pulmonary Hypertension With Heart Failure and Preserved Left Ventricular Ejection Fraction (PH-HFpEF)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2019

At a glance

  • Drugs Levosimendan (Primary)
  • Indications Pulmonary hypertension
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Tenax Therapeutics

    • Most Recent Events

    • 06 Dec 2018 Status changed from not yet recruiting to recruiting.
    • 08 Nov 2018 Planned initiation date changed from 1 Oct 2018 to 1 Dec 2018.
    • 04 Apr 2018 According to a Tenax Therapeutics media release, the company will finalize trial protocol for IND submission and continue preparations to start of the trial by late June or July.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top